# Cannabis Linked to Major Memory and Health Risks – Clinical Review > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-memory-impairment-health-risks-clinical-review/ > **Published:** 2026-03-17T13:34:43-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:06:04-04:00 > **Clinical Summary:** Explore cannabis memory impairment and related health risks. Understand clinical insights on cognitive effects and cannabinoid hyperemesis syndrome. --- ✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. NeurologyMental HealthSafetyResearchTHC Clinical Summary # Clinical Summary Recent evidence indicates that [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) is associated with significant cognitive impairment, particularly affecting memory function, alongside broader health risks that warrant clinical attention when evaluating patients with cannabis exposure. The endocannabinoid system’s role in memory consolidation and retrieval provides a neurobiological mechanism for these observed deficits, which can persist beyond the acute intoxication period and may have cumulative effects with chronic use. Additionally, cannabis-related adverse effects, including [cannabinoid hyperemesis](https://cedclinic.com/cannabis-hyperemesis-syndrome-virginia-er-cases-surge/) syndrome, can produce prolonged symptomatic periods requiring symptomatic management, with complete abstinence representing the only established definitive treatment. These findings suggest that clinicians should routinely screen for memory complaints and cognitive changes in cannabis-using patients and counsel them regarding both acute and long-term neurological risks. Patients should be counseled that while symptomatic relief strategies such as hot water immersion may provide temporary benefit for certain cannabis-related conditions, sustained improvement requires cessation of use. Dr. Caplan’s Take “What we’re seeing with cannabinoid hyperemesis syndrome is a real and reproducible condition in heavy cannabis users, particularly with high-potency products, and it requires us to have honest conversations with patients about dose-dependent risks rather than treating cannabis as uniformly safe just because it’s plant-derived.” Clinical Perspective ⚠️ While [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) and cannabinoid hyperemesis syndrome represent genuine clinical concerns, the framing of “major memory and health risks” warrants careful interpretation given the summary’s limited detail and the broader evidence landscape. Cognitive effects from cannabis are dose and frequency dependent, with some reversibility after cessation, though heavy adolescent use does show associations with sustained memory impairment. Cannabinoid hyperemesis syndrome, though distressing and occasionally requiring hospitalization, remains relatively rare and primarily affects chronic heavy users. Clinicians should routinely screen for cannabis use patterns and educate patients about dose-response relationships and developmental vulnerability, while recognizing that occasional or moderate use carries different risk profiles than daily consumption. A practical approach involves assessing frequency and quantity during substance use screening, discussing specific cognitive or gastrointestinal symptoms, and tailoring counseling intensity based on individual use patterns and life stage rather than applying blanket warnings about cannabis use 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Cannabis+linked+to+major+memory+and+health+risks+-+MSN+%40drcaplan&url=https%3A%2F%2Fwww.msn.com%2Fen-us%2Fnews%2Finsight%2Fcannabis-linked-to-major-memory-and-health-risks%2Fgm-GM3A653505%3FgemSnapshotKey%3DGM3A653505-snapshot-0%26uxmode%3Druby)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.msn.com%2Fen-us%2Fnews%2Finsight%2Fcannabis-linked-to-major-memory-and-health-risks%2Fgm-GM3A653505%3FgemSnapshotKey%3DGM3A653505-snapshot-0%26uxmode%3Druby)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Cannabis+linked+to+major+memory+and+health+risks+-+MSN+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.msn.com%2Fen-us%2Fnews%2Finsight%2Fcannabis-linked-to-major-memory-and-health-risks%2Fgm-GM3A653505%3FgemSnapshotKey%3DGM3A653505-snapshot-0%26uxmode%3Druby)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [CED Digest: 230 Items — March 15, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-clinical-relevance-2026/) - [CED Digest: 436 Items — March 14, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 405 Items — March 12, 2026](https://cedclinic.com/alabama-medical-cannabis-sales-2026-spring-launch/) 📰 Source: [https://www.msn.com/en-us/news/insight/cannabis-linked-to-major-memory-and-health-risks/gm-GM3A653505?gemSnapshotKey=GM3A653505-snapshot-0&uxmode=ruby](https://www.msn.com/en-us/news/insight/cannabis-linked-to-major-memory-and-health-risks/gm-GM3A653505?gemSnapshotKey=GM3A653505-snapshot-0&uxmode=ruby) Further Reading Evidence Watch[The Brain Science Behind the Munchies – Nautilus Magazine](https://cedclinic.com/cannabis-appetite-stimulation-neuroscience/) Evidence WatchIGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial Cannabis Policy Wire[Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I](https://cedclinic.com/nitazene-synthetic-opioids-temporary-schedule-i-placement/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Marijuana and the brain: Study finds memory and decision-making at risk – Radio 47](https://cedclinic.com/heavy-cannabis-use-cognitive-impairments-memory-decision-risks/) This article explores how marijuana use impacts memory and decision-making abilities, highlighting key research findings. [Read More](https://cedclinic.com/heavy-cannabis-use-cognitive-impairments-memory-decision-risks/) [Cannabis affects childhood brain development, is 'real risk' for teens, UCSD finds in long-term study](https://cedclinic.com/cannabis-affects-childhood-brain-development-is-real-risk-for-teens-ucsd-finds-in-long-term-study/) A long-term study from UCSD reveals the risks cannabis poses to brain development in children and teens. [Learn More](https://cedclinic.com/cannabis-affects-childhood-brain-development-is-real-risk-for-teens-ucsd-finds-in-long-term-study/) [Cannabis Medical Benefits and Risks: What Research Says About Its Health Effects](https://cedclinic.com/cannabis-dosing-protocols-safe-therapeutic-use/) An overview of current research on the medical benefits and health risks associated with cannabis use. [Explore Research](https://cedclinic.com/cannabis-dosing-protocols-safe-therapeutic-use/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).